Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix

Vaccine
B RönnbergB Morein

Abstract

It is well established that ISCOMs function efficiently as an antigen-presenting system and protective immunity has been evoked against a variety of infectious agents. The built-in saponin adjuvant from Quillaja saponaria Molina is responsible for the strong immunoenhancing activity displayed by the ISCOM. However, to allow the use of ISCOMs in human vaccines it is necessary to determine the immunological properties and toxicity of chemically defined Quillaja components. Thus, the present study was carried out in a mouse model to determine the adjuvant activity and toxicity of "free", isolated Quillaja components, as well as formulated into particles, i.e. ISCOM matrix. The purified Quillaja components and the ISCOM matrix formulations were examined for their adjuvant activity in a model system consisting of purified influenza virus antigen and Quillaja saponins. It was demonstrated that a Quillaja component, designated QH-C, either as a "free" component or in an ISCOM matrix, has a strong adjuvant activity, but little or no toxicity in the doses tested. In addition, QH-C in the form of ISCOM matrix does not induce any local reactions at the site of injection. Thus, ISCOMs containing the QH-C component, devoid of toxicity, but ...Continue Reading

References

Sep 1, 1992·Scandinavian Journal of Immunology·M Villacres-ErikssonB Morein
Feb 25, 1991·Biochimica Et Biophysica Acta·G F KerstenD J Crommelin
Apr 2, 1987·Journal of Immunological Methods·K LövgrenB Morein
Jan 1, 1989·Sub-cellular Biochemistry·S HöglundB Morein

❮ Previous
Next ❯

Citations

Jun 17, 2006·Pharmaceutical Research·Karen WhiteSarah Hook
Aug 1, 1996·Parasitology Today·A LundénA Uggla
Mar 29, 2005·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Berta Levavi-SivanZohar Kerem
Jun 11, 1998·Phytochemistry·S GuoB G Sundquist
Jun 6, 2000·Advanced Drug Delivery Reviews·C W ToddM J Newman
Jun 6, 2000·Advanced Drug Delivery Reviews·J C CoxI G Barr
Jun 6, 2000·Advanced Drug Delivery Reviews·A Sjölander, J C Cox
Feb 1, 1997·Vaccine·J C Cox, A R Coulter
Feb 1, 1996·Immunology and Cell Biology·I G Barr, G F Mitchell
Oct 16, 1999·Scandinavian Journal of Immunology·S BehboudiM C Villacres-Eriksson
Jul 31, 1998·Immunology and Cell Biology·J Kovarik, C A Siegrist
Jul 31, 1998·Immunology and Cell Biology·R E SmithA M Mowat
Oct 14, 2004·Immunology and Cell Biology·Nikolai Petrovsky, Julio César Aguilar
Nov 13, 1998·Journal of Pharmaceutical Sciences·M J NewmanM Balusubramanian
Dec 17, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Johan BankeforsLennart Kenne
May 20, 2009·Vaccine·Hong-Xiang SunYi-Ping Ye
Apr 21, 2009·International Journal of Pharmaceutics·Hoang L PhamNigel M Davies
Jul 1, 2008·Vaccine·Warren T McBurneySarah Hook
Mar 11, 2008·Biochemical and Biophysical Research Communications·Anthony D CristilloRanajit Pal
Jun 23, 2005·The Journal of Pharmacy and Pharmacology·Dirk G LendemansThomas Rades

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.